Department of Internal Medicine, College of Medicine, King Faisal University, Al-Hasa, Saudi Arabia.
Department of Medicine, Botukatu School of Medicine, Sao Paulo, Brazil.
Clin J Am Soc Nephrol. 2023 Apr 1;18(4):512-520. doi: 10.2215/CJN.0000000000000059. Epub 2022 Jan 13.
Peritoneal dialysis (PD) as an AKI treatment in adults was widely accepted in critical care settings well into the 1980s. The advent of extracorporeal continuous KRT led to widespread decline in the use of PD for AKI across high-income countries. The lack of familiarity and comfort with the use of PD in critical care settings has also led to lack of use even among those receiving maintenance PD. Many critical care units reflexively convert patients receiving maintenance PD to alternative dialysis therapies at admission. Renewed interest in the use of PD for AKI therapy has emerged due to its increasing use in low- and middle-income countries. In high-income countries, the coronavirus disease 2019 (COVID-19) pandemic, saw PD for AKI used early on, where many critical care units were in crisis and relied on PD use when resources for other AKI therapy modalities were limited. In this review, we highlight advantages and disadvantages of PD in critical care settings and indications and contraindications for its use. We provide an overview of literature to support both PD treatment during AKI and its continuation as a maintenance therapy during critical illness. For AKI therapy, we further discuss establishment of PD access, PD prescription management, and complication monitoring and treatment. Finally, we discuss expansion in the use of PD for AKI therapy extending beyond its role during times of resource constraints.
腹膜透析(PD)作为成人急性肾损伤(AKI)的治疗方法,在 20 世纪 80 年代广泛应用于重症监护病房。体外连续肾脏替代治疗(KRT)的出现导致高收入国家 PD 在 AKI 治疗中的应用广泛减少。由于对 PD 在重症监护环境中的使用缺乏熟悉和信心,即使在接受维持性 PD 的患者中,PD 的使用也较少。许多重症监护病房在患者入院时会本能地将接受维持性 PD 的患者转换为其他透析治疗。由于 PD 在中低收入国家的使用日益增加,对 PD 治疗 AKI 的兴趣重新出现。在高收入国家,2019 年冠状病毒病(COVID-19)大流行早期就开始使用 PD 治疗 AKI,当时许多重症监护病房都处于危机之中,当其他 AKI 治疗模式的资源有限时,依赖 PD 的使用。在这篇综述中,我们强调了 PD 在重症监护环境中的优缺点,以及其使用的适应证和禁忌证。我们概述了支持 PD 在 AKI 治疗期间使用及其在危重病期间作为维持治疗的文献。对于 AKI 治疗,我们进一步讨论了 PD 通路的建立、PD 处方管理以及并发症的监测和治疗。最后,我们讨论了 PD 在 AKI 治疗中的应用扩展,超越了资源有限时期的作用。